Shoulder Innovations' Losses Widen Despite Revenue Surge

Ticker: SI · Form: 10-Q · Filed: 2025-09-09T00:00:00.000Z

Sentiment: bearish

Topics: Medical Devices, Biotechnology, Losses, Revenue Growth, Preferred Stock, Cash Burn, Early Stage Company

Related Tickers: SI

TL;DR

Shoulder Innovations is burning cash fast, with losses ballooning despite revenue growth, making it a risky bet for short-term traders.

AI Summary

Shoulder Innovations, Inc. (SI) reported a significant increase in net revenue for the six months ended June 30, 2025, reaching $21.145 million, up from $15.444 million in the prior year, representing a 36.9% increase. Despite this revenue growth, the company's net loss widened substantially to $23.858 million for the six-month period, compared to a net loss of $7.772 million in the same period of 2024. This increased loss was primarily driven by a $11.719 million change in the fair value of the Series E purchase option and higher selling, general, and administrative expenses, which rose to $23.351 million from $16.876 million. The company also saw a substantial increase in cash and cash equivalents, jumping from $6.123 million at December 31, 2024, to $27.054 million at June 30, 2025, largely due to $39.553 million in proceeds from Series E convertible preferred stock. Total assets grew to $77.829 million from $43.080 million, while total liabilities increased to $29.329 million from $23.300 million. The company continues to operate at a significant accumulated deficit, which reached $80.899 million as of June 30, 2025.

Why It Matters

For investors, the significant increase in net loss to $23.858 million, despite strong revenue growth, signals ongoing profitability challenges and reliance on external financing, as evidenced by the $39.553 million Series E preferred stock proceeds. This could impact investor confidence and the stock's valuation, especially given the company's 'Non-accelerated filer' and 'Smaller reporting company' status. Employees might face uncertainty if the company's path to profitability remains unclear, potentially affecting job security or future compensation. Customers, primarily hospitals and surgeons, benefit from the company's continued investment in R&D ($2.989 million for six months) and product development, but the financial instability could raise concerns about long-term product support. In the competitive medical device market, SI's widening losses could make it harder to compete with larger, more established players, potentially limiting its market share growth.

Risk Assessment

Risk Level: high — The company reported a net loss of $23.858 million for the six months ended June 30, 2025, a significant increase from $7.772 million in the prior year, indicating a worsening financial performance. Its accumulated deficit reached $80.899 million, and the company explicitly states it has a 'history of significant net losses' and 'expects to incur operating losses in the future,' with no guarantee of achieving profitability. Furthermore, the company is a 'Non-accelerated filer' and 'Smaller reporting company,' often associated with higher risk.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence on Shoulder Innovations, Inc. Given the widening net losses and significant accumulated deficit, potential investors should scrutinize the company's long-term financing strategy and path to profitability before considering any investment. Existing investors should re-evaluate their position, considering the high risk profile.

Financial Highlights

debt To Equity
N/A
revenue
$21.145M
operating Margin
N/A
total Assets
$77.829M
total Debt
$14.784M
net Income
-$23.858M
eps
N/A
gross Margin
N/A
cash Position
$27.054M
revenue Growth
+36.9%

Revenue Breakdown

SegmentRevenueGrowth
Total Net Revenue$21.145M+36.9%
Q2 2025 Net Revenue$11.013M+33.3%

Key Numbers

Key Players & Entities

FAQ

What were Shoulder Innovations' net revenues for the six months ended June 30, 2025?

Shoulder Innovations, Inc. reported net revenues of $21.145 million for the six months ended June 30, 2025. This represents a significant increase from $15.444 million reported for the same period in 2024.

How much was Shoulder Innovations' net loss for the second quarter of 2025?

For the three months ended June 30, 2025, Shoulder Innovations, Inc. reported a net loss of $19.196 million. This is a substantial increase compared to the net loss of $4.172 million for the three months ended June 30, 2024.

What caused the significant increase in Shoulder Innovations' net loss?

The significant increase in Shoulder Innovations' net loss was primarily driven by a $11.719 million change in the fair value of the Series E purchase option. Additionally, selling, general, and administrative expenses rose to $23.351 million for the six months ended June 30, 2025, from $16.876 million in the prior year.

How much cash and cash equivalents did Shoulder Innovations have as of June 30, 2025?

As of June 30, 2025, Shoulder Innovations, Inc. had $27.054 million in cash and cash equivalents. This is a notable increase from $6.123 million reported at December 31, 2024.

What was the primary source of cash for Shoulder Innovations during the first half of 2025?

The primary source of cash for Shoulder Innovations, Inc. during the six months ended June 30, 2025, was $39.553 million in proceeds from Series E convertible preferred stock, net of issuance costs.

What is Shoulder Innovations' accumulated deficit as of June 30, 2025?

Shoulder Innovations, Inc.'s accumulated deficit as of June 30, 2025, stood at $80.899 million. This indicates the cumulative net losses the company has incurred since its inception.

Is Shoulder Innovations considered a large accelerated filer?

No, Shoulder Innovations, Inc. is not a large accelerated filer. The company indicated by check mark that it is a 'Non-accelerated filer,' a 'Smaller reporting company,' and an 'Emerging growth company' in its 10-Q filing.

What are the key risks highlighted by Shoulder Innovations in its 10-Q filing?

Key risks highlighted include a history of significant net losses and expected future operating losses, substantial debt, the need for additional funding, intense competition, and dependence on the adoption of its implant systems by healthcare facilities and surgeons. The company also faces risks related to product liability claims and downward pricing pressure on medical products.

How has Shoulder Innovations' total convertible preferred stock changed?

Shoulder Innovations, Inc.'s total convertible preferred stock increased significantly to $126.700 million as of June 30, 2025, from $74.475 million as of December 31, 2024. This increase is largely due to the issuance of Series E preferred stock.

What is the impact of the reverse stock split on Shoulder Innovations' shares?

On July 23, 2025, Shoulder Innovations, Inc. effected a reverse stock split of its common stock on a 1-for-19.08 basis. All impacted share and per-share information in the financial statements have been retroactively adjusted to reflect this split.

Risk Factors

Industry Context

The orthopedic device market, particularly for shoulder implants, is competitive and driven by technological innovation and surgeon adoption. Companies like Shoulder Innovations, Inc. focus on developing advanced solutions to improve patient outcomes and surgical efficiency. The industry is subject to regulatory oversight and reimbursement policies that can impact market access and growth.

Regulatory Implications

As a medical device company, Shoulder Innovations, Inc. is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance is critical. Any failure to adhere to these regulations could result in product recalls, fines, or market withdrawal, impacting financial performance and investor confidence.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Accumulated Deficit
The total net losses of a company that have not been offset by net income since its inception. (Indicates the company has historically incurred more expenses than revenues, reaching $80.899 million as of June 30, 2025.)
Convertible Preferred Stock
A class of preferred stock that can be converted into a specified number of common stock shares. (The company issued Series E convertible preferred stock, raising significant capital ($39.553M) and increasing total convertible preferred stock to $126.700M.)
Fair Value of Series E Purchase Option
The estimated market value of the option to purchase Series E preferred stock. (A change in this fair value of $11.719M significantly impacted the net loss for the period.)
Series E Convertible Preferred Stock
A specific series of preferred stock with conversion rights, issued by Shoulder Innovations, Inc. (The issuance of this stock was the primary driver for the increase in cash and cash equivalents.)
Stockholders' Deficit
The negative equity position of a company when liabilities exceed assets, or when accumulated losses exceed contributed capital. (The company has a total stockholders' deficit of ($78.200M) as of June 30, 2025, primarily due to its accumulated deficit.)

Year-Over-Year Comparison

Shoulder Innovations, Inc. has demonstrated strong top-line growth, with net revenue increasing by 36.9% for the six months ended June 30, 2025, compared to the prior year. However, this growth has been overshadowed by a significantly widened net loss, which more than tripled year-over-year. While cash reserves have substantially increased due to a large preferred stock issuance, operating expenses, particularly SG&A, have also risen considerably, leading to a higher cash burn from operations. New risks related to the fair value of financial instruments have emerged as a key factor impacting profitability.

Filing Stats: 4,706 words · 19 min read · ~16 pages · Grade level 17.9 · Accepted 2025-09-09 16:12:03

Key Financial Figures

Filing Documents

- Financial Information

Part I - Financial Information

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 5 Condensed Balance Sheets (unaudited) 5 Condensed Statements of Operations and Comprehensive Loss (unaudited) 7 Condensed Statements of Changes in Convertible Preferred Stock and Stockholder's Deficit (unaudited) 8 Condensed Statements of Cash Flows (unaudited) 9 Notes to the Unaudited Condensed Financial Statements 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 29

Controls and Procedures

Item 4. Controls and Procedures 29

- Other Information

Part II - Other Information

Legal Proceedings

Item 1. Legal Proceedings 31

Risk Factors

Item 1A. Risk Factors 31

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 80

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 81

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 81

Other Information

Item 5. Other Information 81

Exhibits

Item 6. Exhibits 81

Signatures

Signatures 83

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," " contemplates," "believes," "estimates," "forecasts," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed in Part II, Item 1A "Risk Factors" in this Quarterly Report on Form 10-Q. The forward-looking statements in this Quarterly Report on Form 10-Q are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements June 30, 2025 December 31, 2024 Assets Current Assets Cash and cash equivalents $ 27,054 $ 6,123 Marketable securities 12,581 8,921 Trade accounts receivable, net of allowance for credit losses 6,886 5,122 Inventories, net 17,081 13,955 Prepaid expenses 691 431 Other current assets 4,618 573 Total Current Assets 68,911 35,125 Property and equipment, net 8,506 7,487 Operating lease right-of-use asset 162 68 Intangible assets, net 250 400 Total Assets 77,829 43,080 Liabilities, Convertible Preferred Stock, and Stockholders' Deficit Current Liabilities Accounts payable ($ 673 and $ 813 to related parties, respectively) 6,042 4,860 Current operating lease obligations 82 47 Accrued liabilities 6,370 2,740 Total Current Liabilities 12,494 7,647 Long-Term Liabilities Preferred stock warrant liability 1,967 970 Long-term debt 14,784 14,658 Other long-term liabilities 84 25 Total Long-Term Liabilities 16,835 15,653 Total Liabilities 29,329 23,300 Commitments and contingencies (note 8) Convertible Preferred Stock Series Seed, $ 0.001 par value, 16,840,400 shares authorized, and 16,840,400 and 15,851,401 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 1,420 1,337 Series A, $ 0.001 par value, 22,399,370 shares authorized, issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 5,600 5,600 Series B, $ 0.001 par value, 6,913,964 shares authorized, and 6,663,964 and 5,913,964 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 2,897 2,200 Series C, $ 0.001 par value, 50,116,284 shares authorized, issued, and outstanding as of June 30, 2025 and December 31, 2024, respectively 21,550 21,550 Series D, $ 0.001 par value, 83,403,626 shares authorized, and 80,909,169 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 43,788 43,788 Series E, $ 0.001 par value, 58,774,332 shares authorized, and 58,774,31

View on Read The Filing